Clinical trials data
N-Back Task in schizophrenia and psychosis trials: 66 registered studies
Every registered schizophrenia and psychosis study on ClinicalTrials.gov that names the N-Back Task in an outcome measure: how often it is a primary outcome, the tests named with it, how large the studies are and when they measure it.
- Registered schizophrenia and psychosis studies name it in an outcome measure
- 66
- Name it in a primary outcome, 48%
- 32 of 66
Tests named in the same studies
- 1
Continuous Performance Test13 studies, 5 as a primary outcome
- 2
AX Continuous Performance Test9 studies, 7 as a primary outcome
- 3
Verbal Learning8 studies, 5 as a primary outcome
- 4
Verbal Fluency7 studies, 3 as a primary outcome
- 5
Digit Span Test6 studies, 1 as a primary outcome
- 6
Monetary Incentive Delay5 studies, 3 as a primary outcome
- 7
Tower Planning5 studies, 2 as a primary outcome
- 8
Stroop Color-Word Test5 studies, 1 as a primary outcome
- 9
Paced Visual Serial Addition Test4 studies, 2 as a primary outcome
- 10
Card Sorting Test (Berg)4 studies, 1 as a primary outcome
A test as a primary outcomeOnly in secondary or other outcomes
Studies by start year
A test as a primary outcomeOnly in secondary or other outcomes
Show as a table
| Start year | Studies | A test as a primary outcome |
|---|---|---|
| 2000 | 0 | 0 |
| 2001 | 0 | 0 |
| 2002 | 1 | 1 |
| 2003 | 1 | 1 |
| 2004 | 0 | 0 |
| 2005 | 2 | 2 |
| 2006 | 3 | 1 |
| 2007 | 5 | 3 |
| 2008 | 2 | 0 |
| 2009 | 1 | 1 |
| 2010 | 2 | 1 |
| 2011 | 5 | 2 |
| 2012 | 5 | 2 |
| 2013 | 6 | 3 |
| 2014 | 3 | 2 |
| 2015 | 2 | 2 |
| 2016 | 4 | 3 |
| 2017 | 2 | 0 |
| 2018 | 4 | 1 |
| 2019 | 3 | 2 |
| 2020 | 1 | 0 |
| 2021 | 0 | 0 |
| 2022 | 3 | 1 |
| 2023 | 0 | 0 |
| 2024 | 1 | 1 |
| 2025 | 3 | 0 |
| 2026 | 6 | 2 |
Phases and study sizes
By phase
- Early phase 11 studies, 1 as a primary outcome
- Phase 18 studies, 4 as a primary outcome
- Phase 1/21 studies, 0 as a primary outcome
- Phase 214 studies, 9 as a primary outcome
- Phase 32 studies, 2 as a primary outcome
- Phase 45 studies, 2 as a primary outcome
- Not applicable34 studies, 14 as a primary outcome
- Observational1 studies, 0 as a primary outcome
Participants per study
- Phase 243 median, 18 to 102
- Not applicable60 median, 25 to 83
Show as a table
| Phase | Studies with a size | Median | Middle half |
|---|---|---|---|
| Phase 2 | 14 | 43 | 18 to 102 |
| Not applicable | 34 | 60 | 25 to 83 |
When schizophrenia and psychosis trials measure it
Latest time point of each outcome
- Within a day7 outcomes, 5 as a primary outcome
- Up to 4 weeks25 outcomes, 12 as a primary outcome
- 1 to 3 months18 outcomes, 9 as a primary outcome
- 3 to 6 months7 outcomes, 4 as a primary outcome
- 6 to 12 months3 outcomes, 0 as a primary outcome
- No duration given6 outcomes, 2 as a primary outcome
A test as a primary outcomeOnly in secondary or other outcomes
60 of the 66 outcome measures give a duration. A single visit counts as within a day.
Status, results, interventions and countries
Status
- Recruiting6 studies, 2 as a primary outcome
- Not yet recruiting6 studies, 3 as a primary outcome
- Active, not recruiting3 studies, 3 as a primary outcome
- Completed38 studies, 17 as a primary outcome
- Stopped early5 studies, 4 as a primary outcome
- Status unknown8 studies, 3 as a primary outcome
What they test
- Behavioral8 studies, 5 as a primary outcome
- Drug32 studies, 17 as a primary outcome
- Device22 studies, 9 as a primary outcome
- Procedure3 studies, 2 as a primary outcome
- Other8 studies, 4 as a primary outcome
- None given1 studies, 0 as a primary outcome
Intervention types as registered. A study can list several; observational studies often list none.
Where their sites are
- United States28 studies, 17 as a primary outcome
- Canada8 studies, 5 as a primary outcome
- China5 studies, 0 as a primary outcome
- Germany4 studies, 2 as a primary outcome
- South Korea3 studies, 1 as a primary outcome
- United Kingdom3 studies, 2 as a primary outcome
- Taiwan2 studies, 0 as a primary outcome
- Belgium1 studies, 1 as a primary outcome
- Brazil1 studies, 0 as a primary outcome
- France1 studies, 0 as a primary outcome
- Iran1 studies, 1 as a primary outcome
- Spain1 studies, 0 as a primary outcome
13 countries in all. A study with sites in several counts in each; 7 list no site.
Reported results
Completed studies with results posted on ClinicalTrials.gov, a results paper the registry links to the study, or both.
Completed schizophrenia and psychosis studies that name the N-Back Task: 21 of 38, 55%
Every completed study with a cognitive outcome: 3,626 of 7,953, 46%
| Results | Completed schizophrenia and psychosis studies that name the N-Back Task | Every completed study |
|---|---|---|
| Results on ClinicalTrials.gov and a paper | 7, 18% | 776, 10% |
| Results on ClinicalTrials.gov only | 4, 11% | 1,139, 14% |
| A results paper only | 10, 26% | 1,711, 22% |
| Neither | 17, 45% | 4,327, 54% |
The 66 studies
66 studies match. 32 name the N-Back Task in a primary outcome. Median size 58 participants. Median time to the primary outcome: 4 weeks.
Loading 66 studies; the filters turn on when they arrive.
2026 is partly planned starts. Not shown: 1 planned to start after 2026.
Show as a table
| Start year | Studies | As a primary outcome |
|---|---|---|
| 2000 | 0 | 0 |
| 2001 | 0 | 0 |
| 2002 | 1 | 1 |
| 2003 | 1 | 1 |
| 2004 | 0 | 0 |
| 2005 | 2 | 2 |
| 2006 | 3 | 1 |
| 2007 | 5 | 3 |
| 2008 | 2 | 0 |
| 2009 | 1 | 1 |
| 2010 | 2 | 1 |
| 2011 | 5 | 2 |
| 2012 | 5 | 2 |
| 2013 | 6 | 3 |
| 2014 | 3 | 2 |
| 2015 | 2 | 2 |
| 2016 | 4 | 3 |
| 2017 | 2 | 0 |
| 2018 | 4 | 1 |
| 2019 | 3 | 2 |
| 2020 | 1 | 0 |
| 2021 | 0 | 0 |
| 2022 | 3 | 1 |
| 2023 | 0 | 0 |
| 2024 | 1 | 1 |
| 2025 | 3 | 0 |
| 2026 | 6 | 2 |
Library tests named most
Conditions
Phases
Participants
Lead sponsor: industry 10, NIH 2, other 54. Interventional 65, observational 1.
As a primary outcomeSecondary or other outcomeThe N-Back Task
The studies, newest registration first
Each number opens the study's record on ClinicalTrials.gov.
| Study | Start | Phase | Conditions | Participants | Lead sponsor | Status | Library tests named, with the latest time point |
|---|---|---|---|---|---|---|---|
| NCT07806877 | Start2026 | PhaseNot applicable | ConditionsSchizophrenia and psychosis | Participants60 | Lead sponsorOther | StatusNot yet recruiting | Library tests named
|
| NCT07659938 | Start2027 | PhaseNot applicable | ConditionsSchizophrenia and psychosis | Participants30 | Lead sponsorIndustry | StatusNot yet recruiting | Library tests named
|
| NCT07592169 | Start2026 | PhasePhase 2 | ConditionsSchizophrenia and psychosis | Participants104 | Lead sponsorOther | StatusNot yet recruiting | Library tests named
|
| NCT07342465 | Start2026 | PhaseNot applicable | ConditionsSchizophrenia and psychosis | Participants20 | Lead sponsorOther | StatusNot yet recruiting | Library tests named
|
| NCT07226895 | Start2026 | PhasePhase 1/2 | ConditionsSchizophrenia and psychosis | Participants150 | Lead sponsorIndustry | StatusRecruiting | Library tests named
|
| NCT07006935 | Start2026 | PhaseNot applicable | ConditionsSchizophrenia and psychosis | Participants30 | Lead sponsorOther | StatusRecruiting | Library tests named
|
| NCT06936397 | Start2025 | PhaseNot applicable | ConditionsSchizophrenia and psychosis | Participants60 | Lead sponsorOther | StatusRecruiting | Library tests named
|
| NCT06907420 | Start2025 | PhaseNot applicable | ConditionsSchizophrenia and psychosis | Participants20 | Lead sponsorOther | StatusRecruiting | Library tests named
|
| NCT06904092 | Start2026 | PhaseNot applicable | ConditionsSchizophrenia and psychosis | Participants140 | Lead sponsorOther | StatusNot yet recruiting | Library tests named
|
| NCT06880328 | Start2018 | PhasePhase 1 | ConditionsSchizophrenia and psychosis | Participants35 | Lead sponsorIndustry | StatusCompleted | Library tests named
|
| NCT06740747 | Start2025 | PhaseNot applicable | ConditionsSchizophrenia and psychosis | Participants60 | Lead sponsorOther | StatusRecruiting | Library tests named
|
| NCT06315972 | Start2024 | PhasePhase 2 | ConditionsSchizophrenia and psychosis | Participants90 | Lead sponsorOther | StatusNot yet recruiting | Library tests named
|
| NCT05695144 | Start2022 | PhaseNot applicable | ConditionsSchizophrenia and psychosis | Participants120 | Lead sponsorOther | StatusStatus unknown | Library tests named
|
| NCT05582980 | Start2020 | PhaseNot applicable | ConditionsSchizophrenia and psychosis | Participants60 | Lead sponsorOther | StatusCompleted | Library tests named
|
| NCT05310955 | Start2022 | PhaseNot applicable | ConditionsSchizophrenia and psychosis | Participants60 | Lead sponsorOther | StatusStatus unknown | Library tests named
|
| NCT05200962 | Start2022 | PhasePhase 1 | ConditionsSchizophrenia and psychosis | Participants30 | Lead sponsorOther | StatusStatus unknown | Library tests named
|
| NCT04545294 | Start2019 | PhaseNot applicable | ConditionsSchizophrenia and psychosis | Participants36 | Lead sponsorOther | StatusCompleted | Library tests named
|
| NCT04296604 | Start2014 | PhaseNot applicable | ConditionsBrain injury and concussion, Schizophrenia and psychosis, Depression and bipolar disorder, ADHD, Substance use and addiction | Participants600 | Lead sponsorOther | StatusRecruiting | Library tests named
|
| NCT03896438 | Start2019 | PhaseNot applicable | ConditionsSchizophrenia and psychosis | Participants12 | Lead sponsorOther | StatusCompleted | Library tests named
|
| NCT03868358 | Start2017 | PhaseNot applicable | ConditionsSchizophrenia and psychosis | Participants60 | Lead sponsorOther | StatusCompleted | Library tests named
|
| NCT03756610 | Start2018 | PhaseNot applicable | ConditionsSchizophrenia and psychosis | Participants90 | Lead sponsorOther | StatusStatus unknown | Library tests named
|
| NCT03621540 | Start2018 | PhaseNot applicable | ConditionsSchizophrenia and psychosis | Participants37 | Lead sponsorOther | StatusCompleted | Library tests named
|
| NCT03208036 | Start2018 | PhaseNot applicable | ConditionsSchizophrenia and psychosis, Depression and bipolar disorder | Participants22 | Lead sponsorOther | StatusCompleted | Library tests named
|
| NCT03188133 | Start2017 | PhaseNot applicable | ConditionsSchizophrenia and psychosis | Participants90 | Lead sponsorOther | StatusStatus unknown | Library tests named
|
| NCT02928965 | Start2013 | PhasePhase 2 | ConditionsSchizophrenia and psychosis | Participants207 | Lead sponsorOther | StatusCompleted | Library tests named
|
Questions, answered from the data
How many schizophrenia and psychosis trials use the N-Back Task?
66 registered schizophrenia and psychosis studies on ClinicalTrials.gov name it in an outcome measure, 32 of them in a primary outcome: 10% of the condition's 640 studies with a cognitive outcome, against 5% of all of them. It is the 5th most named test in schizophrenia and psychosis trials.
Which tests do schizophrenia and psychosis trials use with the N-Back Task?
The Continuous Performance Test (13 studies), the AX Continuous Performance Test (9 studies) and Verbal Learning (8 studies).
How many participants do phase 2 schizophrenia and psychosis trials that use the N-Back Task enroll?
Half of the phase 2 studies that name it enroll 43 participants or fewer, and the middle half enroll 18 to 102. 14 of them give a size.
When do schizophrenia and psychosis trials measure the N-Back Task?
Half of the primary outcomes that name the N-Back Task are measured within 4 weeks of the start, and the middle half from 4 days to 12 weeks. 30 primary outcomes give a duration.
How many completed schizophrenia and psychosis trials that use the N-Back Task have reported results?
21 of the 38 completed studies that name it, 55%, have reported results: 11 posted them on ClinicalTrials.gov, 17 have a results paper linked to the registry record, and 7 did both. The other 17 show neither. Of all completed studies with a cognitive outcome, 46% have reported results.
How the studies are counted
For each test family, the census runs ClinicalTrials.gov's own outcome search for the family's names and reads every study first posted by the day the family was counted. These studies were read on 10 November 2026. A study counts once on a page, however many tests it names. Counts for a test cover every version of the task under any of its names, so a page can count studies that used a commercial version.
The census adds two things to each record and changes nothing in it: which outcome list names the test (primary, then secondary, then other), and the condition groups, matched on the study's condition names and MeSH terms. A study can fall in several groups; one whose only condition is cognitive impairment or decline falls in “Cognitive impairment and decline”. Studies that name only instruments outside the library count in every total and share but are not listed.
A second read on 10 November 2026 added each study's overall status, whether results are posted, its intervention types, the countries of its sites and the time frame of the outcome that names each test. A time frame counts by the latest time point it names: “Baseline, 12 and 24 weeks” is 24 weeks, a single visit is within a day, and one that names no duration, such as “end of treatment”, is left out of the timings.
A third read on 10 November 2026 added the papers the registry links to each study: those its sponsor lists as reporting results, and those PubMed links to it through the study's NCT number. A study has a results paper when one of them came out in or after the month of its primary completion and PubMed does not class it as a protocol, review or comment. A paper that never gives the NCT number is not linked, so some studies counted as reporting neither did publish.
Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine, which does not endorse these pages. Every study line is in the data release 2.1.0, and the explorer's own file is clinical-trials-studies.json.
The census counts 1-Back Task and 2-Back Task as one test family, so this page counts their studies together.
Run the N-Back Task in your trial
Choose tests with a record in registered trials, and run them in a browser at every site, on the same version each visit.